IlYang Dapagliflozin Extended-Release Tablet 10/1000 mg
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
IlYang Pharmaceutical Co., Ltd.
MFDS item code 202106876 · Approved 2021.10.12
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps adult patients with type 2 diabetes to control their blood sugar when used in combination with dapagliflozin and metformin. It can effectively manage blood sugar when used alongside dietary and exercise therapies. Especially for patients with cardiovascular diseases or risk factors, it is advisable to refer to expert information regarding the impact of dapagliflozin on the occurrence of cardiovascular events. This medication is used to improve blood sugar control in patients with type 2 diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same metformin dose the patient was taking, or the closest appropriate therapeutic dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously taking. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering agents. Since such a change may cause changes in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine should be swallowed whole and must not be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted by the kidneys and renal function is likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients, Patient subsection).
This medication is used for the treatment of diabetes and helps in controlling blood sugar levels. It may rarely cause a serious condition called lactic acidosis, so caution is needed. Be careful as hypoglycemic symptoms may appear when taken with other diabetes medications. Individuals allergic to any component or additives of this medication should not take it. Patients with moderate to severe renal impairment, dehydration, severe infections, or heart problems should not take this medication. Pregnant or breastfeeding women should also avoid using this medication. This medication should be discontinued for a period before and after surgery, and its use should be resumed only after confirming that kidney function is normal post-surgery. Elderly patients or those with weakened kidney function should closely monitor kidney function before and during the use of this medication, and be aware of symptoms of hypotension or fluid loss. This medication may cause a reduction in body fluid or blood pressure, so if such symptoms occur, immediate consultation with healthcare professionals is advised. Genital and urinary tract infections may occur, so swift treatment should be sought if any signs of infection appear. This medication may lower vitamin B12 levels, so regular periodic testing of vitamin B12 levels is recommended during extended use. Excessive alcohol should be avoided as alcohol may increase the risk of side effects from this medication. Hypoglycemic symptoms may occur, so especially when taking with other hypoglycemic agents, blood sugar levels should be closely monitored. This medication does not significantly impact driving or operating machinery, but caution is advised as symptoms like dizziness may occur. Keep out of reach of children and store in the original container to prevent deterioration in quality.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to protect it from air and moisture, and keep it at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the effectiveness of the medication and prevent degradation.
Yellow, double-sided, convex, oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
IlYang Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.